


**Amendments to the claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended): A compound according to formula (I) ~~hereinbelow~~:



wherein:

R<sub>1</sub> represents NR<sub>4</sub>R<sub>5</sub>;

R<sub>2</sub> represents CONH<sub>2</sub> or SO<sub>2</sub>NH<sub>2</sub>;

R<sub>3</sub> represents up to three substituents selected from the group consisting of halogen, C<sub>1-4</sub>alkyl, NH<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, O-alkyl, S-alkyl, CN, CHO, SO<sub>2</sub>-alkyl, and NO<sub>2</sub>;

R<sub>4</sub> represents H[, ] or C<sub>1-2</sub> alkyl;

R<sub>5</sub> represents C(=A)NHR<sub>6</sub>, COR<sub>7</sub>, or R<sub>6</sub>;

A represents O, S, or N;

R<sub>6</sub> represents H, or C<sub>1-2</sub> alkyl;

R<sub>7</sub> represents C<sub>1-2</sub> alkyl; and

L represents a linker D-E-D such that

D represents a bond or C<sub>1-4</sub> alkyl;



E represents C = C, CONH, NHCO, COO, NH, O, S, or ; and

G and I independently represent H[, ] or C<sub>1-2</sub> alkyl; or a ~~pharmaceutically~~ pharmaceutically acceptable salt thereof, provided that the compound of formula (I) is not 2-[(aminocarbonyl)amino]-5-{[(4-chlorophenyl)methyl]oxyl-3-thiophenecarboxamide.

2. (Original): A compound according to claim 1 wherein R<sub>2</sub> is CONH<sub>2</sub>.
3. (Original): A compound according to claim 1 wherein R<sub>5</sub> is C(=A)NHR<sub>6</sub>.
4. (Original): A compound according to claim 1 wherein A is O.
5. (Original): A compound according to claim 1 wherein E is



6. (Currently amended): A compound according to claim 1 wherein the compound is selected from the group consisting of:

5-[(E)-phenyl]-ethenyl]-2-ureido-thiophene-3-carboxylic acid amide;  
5-[(E)-2-(4-Fluoro-phenyl)- ethenyl]-2-ureido-thiophene-3-carboxylic acidamide;  
5-[(E)-2-(4-Chloro-phenyl)- ethenyl]-2-ureido-thiophene-3-carboxylic acid amide;  
5-Phenethyl-2-ureido-thiophene-3-carboxylic acid amide;  
5-Benzyl-2-ureido-thiophene-3-carboxylic acid amide;  
5-(1-Phenyl-ethyl)-2-ureido-thiophene-3-carboxylic acid amide;  
5-Phenylethynyl-2-ureido-thiophene-3-carboxylic acid amide;  
5-(4-Fluorophenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;  
5-(4-Ethylphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;  
5-(4-Methoxyphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;  
5-(4-Chlorophenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide[[ ]];  
5-(4-Trifluoromethylphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;  
5-(3-Trifluoromethylphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide; and  
5-Acetylamino-thiophene-2,4-dicarboxylic acid 4-amide 2-[(3-chloro-phenyl)-amide]; or a pharmaceutically acceptable salt thereof.

7. (Original): A method of treating a disease characterized by pathological NF-κB activation comprising inhibiting the pathological activation by administering to a patient in need thereof an effective amount of a compound according to claim 1.

8. (Original): A method according to claim 7 wherein the disease is an inflammatory or tissue repair disorder.

9. (Currently amended): A method according to Claim 8 wherein the disease is ~~selected from the group consisting of an~~ inflammatory ~~and or~~ tissue repair ~~disorder disorders,~~ particularly selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, asthma, ~~[[and]]~~ COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis, ~~[[and]]~~ fibrotic disease ~~diseases,~~ dermatosis, ~~including~~ psoriasis, atopic dermatitis, ~~[[and]]~~ ultraviolet radiation (UV)-induced skin damage, ~~autoimmune diseases including~~ systemic lupus erythematosus, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue rejection, ~~[[and]]~~ organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, ~~including~~ Hodgkins disease, cachexia, inflammation associated with infection, ~~and certain viral infections, including acquired~~ inflammation associated with acquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome, and Ataxia Telangiectasia.

10. (Original): A method according to claim 7 wherein said disease is COPD.

11. (Original): A method according to claim 7 wherein said disease is asthma.

12. (Original): A method according to claim 7 wherein said disease is rheumatoid arthritis.

13. (Original): A method according to claim 7 wherein said disease is dermatosis.

14. (Original): A method according to claim 7 wherein the disease is selected from the group consisting of: psoriasis, atopic dermatitis, and UV-induced skin damage.

15. (Currently amended): A method according to claim 7 wherein the disease is selected from the group consisting of ~~autoimmune diseases;~~ tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, osteoarthritis, osteoporosis, and Ataxia Telangiectasia.

16. (Canceled).

17. (Currently amended): A method according to claim [[9]] 7 wherein the ~~autoimmune~~ disease is systemic lupus erythematosus, multiple sclerosis, psoriatic arthritis, [[or]] alkylosing spondylitis, or diabetes.

18. (Currently amended): A method according to claim 7 wherein the disease is cancer [[and]] or cachexia.


19. (Original): A method according to claim 7 wherein the cancer is Hodgkins disease.

20. (Currently amended): A method according to claim 7 wherein the disease is inflammation associated with infection ~~and certain viral infections, including~~ and acquired immune deficiency syndrome (AIDS).

21. (Original): A method according to claim 7 wherein the disease is AIDS.

22. (Original): A method according to claim 7 wherein the disease is adult respiratory distress syndrome.

23. (New): A compound according to claim 1 wherein E is



24. (New): A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient.